Faculty Collaboration Database

A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. Clin Pharmacol Ther 1989 Mar;45(3):312-20

Date

03/01/1989

Pubmed ID

2537699

DOI

10.1038/clpt.1989.34

Scopus ID

2-s2.0-0024498621 (requires institutional sign-in at Scopus site)   19 Citations

Abstract

Benazepril hydrochloride is a nonsulfhydryl, long-acting angiotensin-converting enzyme inhibitor that is orally effective. This study was designed to determine the acute hemodynamic effects of this agent in patients with chronic congestive heart failure. Twenty-six patients with New York Heart Association class III or IV congestive heart failure and left ventricular ejection fractions less than 35%, cardiac indexes less than 2.1 L/min/m2, and pulmonary artery wedge pressures greater than 12 mm Hg were given 2 or 5 mg benazepril hydrochloride. All does produced significant (p less than 0.05) increases in cardiac output (26.7% to 31.6% above control) and heart rate (5.4% to 11.2% above control) and decreases in systemic (27.1% to 32.0% below control) and pulmonary (34.8% to 55.5% below control) vascular resistances, mean pulmonary (25.3% to 30.3% below control) and systemic (13.4% to 18.5% below control) arterial pressures, and pulmonary artery wedge pressure (46.9% to 51.1% below control). Twenty-four hours after an initial dose, systemic vascular resistance and pulmonary artery wedge pressures remained below control levels. Angiotensin-converting enzyme activity fell by 67.8% +/- 6.4%, with a 15.8% +/- 7.6% decline in aldosterone levels. Thus benazepril hydrochloride is an effective angiotensin-converting enzyme inhibitor that produces hemodynamic effects that persist for 24 hours after a single oral dose.

Author List

Insel J, Mirvis DM, Boland MJ, Cinquegrani MP, Shanes J, Rubin SA, Whalen JJ

Author

Michael P. Cinquegrani MD Director, Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aldosterone
Angiotensin-Converting Enzyme Inhibitors
Benzazepines
Captopril
Chronic Disease
Enalapril
Female
Heart Failure
Hemodynamics
Humans
Male
Middle Aged
Multicenter Studies as Topic
Peptidyl-Dipeptidase A
Renin
Time Factors